Business Context and Reporting Period
CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory processes, primarily targeting calcium release-activated calcium (CRAC) channels. The company's lead product candidate is Auxora (zegocractin), currently in Phase 2 trials for acute kidney injury (AKI) and acute pancreatitis (AP). This Form 10-Q covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7.8) million | $(5.6) million | $(18.8) million | $(9.4) million |
| Operating Expenses | $5.6 million | $5.7 million | $18.7 million | $18.0 million |
| Cash & Equivalents | $5.5 million | $9.2 million | $5.5 million | $9.2 million |
| Short-term Investments | $8.6 million | $10.7 million | $8.6 million | $10.7 million |
| Total Liquidity | $14.1 million | $19.9 million | $14.1 million | $19.9 million |
| Long-term Debt (Promissory Note) | $8.9 million | $0 | $8.9 million | $0 |
| Warrant Liability | $2.6 million | $1.7 million | $2.6 million | $1.7 million |
| Accumulated Deficit | $(178.6) million | $(159.8) million | $(178.6) million | $(159.8) million |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss for the nine months ended September 30, 2025, increased to $18.8 million from $9.4 million in the prior year period. This increase was driven by higher operating expenses and the absence of a significant non-cash gain from warrant liability fair value adjustments that benefited the 2024 results ($7.8 million gain in 2024 vs. $0.2 million gain in 2025).
- Debt Financing: In February 2025, the company entered into a Loan Agreement with Avenue Venture Opportunities Fund II, L.P., securing an initial $10.0 million tranche. This resulted in a new long-term promissory note liability of $8.9 million (fair value) and associated interest expense of $1.1 million for the nine months ended September 30, 2025.
- Operating Expenses: Research and development (R&D) expenses increased by 14% year-over-year for the nine-month period ($12.1 million vs. $10.6 million), primarily due to increased clinical trial activities. General and administrative (G&A) expenses decreased by 11% ($6.6 million vs. $7.4 million), largely due to reduced professional service and consultant costs compared to the 2024 private placement transaction costs.
- Liquidity Position: Total cash, cash equivalents, and short-term investments decreased to $14.1 million from $19.9 million at the end of 2024, reflecting cash burn from operations partially offset by financing activities.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Current liquidity is projected to fund operations only into the second half of 2026. The company will require substantial additional capital to complete the development and commercialization of its product candidates.
- Clinical Outlook: The company is conducting a Phase 2 trial (KOURAGE) for Auxora in AKI with data expected in the first half of 2026. A pivotal trial design for acute pancreatitis is expected to be finalized in the first half of 2026.
- Capital Requirements: The company plans to seek additional funding through public/private financings, debt, or collaborations. Failure to secure capital could force delays or elimination of development programs.
- Key Risks:
- Regulatory Uncertainty: Significant portion of the CARPO trial was conducted in India; FDA acceptance of this data is not guaranteed.
- Debt Covenants: The Loan Agreement includes restrictive covenants limiting additional indebtedness, asset sales, and dividends.
- Market Volatility: The company faces risks related to global economic conditions, tariffs, and the volatility of biopharmaceutical stock markets.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the company's immediate plans for raising capital to bridge the gap beyond the second half of 2026.
- Debt Terms: Review the specific milestones required to draw Tranche 2 ($7.5 million) and Tranche 3 ($15.0 million) of the Avenue Loan Agreement and the implications of failing to meet them.
- Clinical Data Acceptance: Assess the FDA's stance on data from the India-based CARPO trial and the potential need for additional U.S.-based trials.
- Warrant Liability Volatility: Monitor the fair value adjustments of the warrant liabilities, which significantly impact reported net loss but are non-cash items.
- ATM Capacity: Confirm the remaining capacity under the At-The-Market (ATM) facility ($2.6 million as of Sept 30, 2025, increased to $9.7 million via a November 2025 supplement) and the pace of share sales.